Other News To Note
KineMed Inc., of Emeryville, Calif., received a Rapid Access to Intervention Development (RAID) grant from the National Institutes of Health for manufacturing, formulation and investigational new drug-enabling safety studies of FX-5A, an ApoA-I mimetic designed to reverse atherosclerosis and heart disease.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter